Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Catalyst PharmaceuticalsCPRX +0.02%70 3-Year Book Growth Rate is 39.70% as of Mar. 2026, which is 55% above its 10-year median of 25.60. GuruFocus rates CPRX with a GF Score™ of 70/100 and a GF Value™ of $25.12 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,123 Biotechnology companies, Catalyst Pharmaceuticals ranks better than 91.54% on this metric.
During the past 12 months, Catalyst Pharmaceuticals's average Book Value per Share Growth Rate was 27.30% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 39.70% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 38.30% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 33.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Catalyst Pharmaceuticals was 425.10% per year. The lowest was -41.30% per year. And the median was 25.60% per year.
Catalyst Pharmaceuticals (NAS:CPRX) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Catalyst Pharmaceuticals 3-Year Book Growth Rate Related Terms
CPRX vs PBLS, ELVN, RLAY: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Catalyst Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catalyst Pharmaceuticals 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Catalyst Pharmaceuticals's 3-Year Book Growth Rate falls into.
Catalyst Pharmaceuticals 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 39.70% mean?
Catalyst Pharmaceuticals (CPRX) has a 3-Year Book Growth Rate of 39.70% as of Mar. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Catalyst Pharmaceuticals and its competitors. This is 55% above median its historical median of 25.60. According to the industry distribution chart, Catalyst Pharmaceuticals ranks #95 out of 1123 companies in the Biotechnology industry, placing it in the top 8.5%.
Is Catalyst Pharmaceuticals' 3-Year Book Growth Rate too high?
Catalyst Pharmaceuticals' current 3-Year Book Growth Rate of 39.70% is 55% above median its 10-year median of 25.60. Based on the distribution chart, Catalyst Pharmaceuticals ranks #95 out of 1123 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Catalyst Pharmaceuticals has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' 3-Year Book Growth Rate compare to PBLS and ELVN?
According to the Biotechnology industry distribution chart, Catalyst Pharmaceuticals ranks #95 out of 1123 companies for 3-Year Book Growth Rate. This places Catalyst Pharmaceuticals in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Catalyst Pharmaceuticals and its competitors. Catalyst Pharmaceuticals's current 3-Year Book Growth Rate is 39.70%, which is 55% above median its own 10-year median of 25.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (CPRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $25.12, compared to a current price of $31.49 — trading 25.4% above its estimated fair value. The current 3-Year Book Growth Rate is 39.70%, which is 55% above median its 10-year median of 25.60. Catalyst Pharmaceuticals' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Catalyst Pharmaceuticals (CPRX), the current 3-Year Book Growth Rate is 39.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catalyst Pharmaceuticals (CPRX) Overvalued in 2026?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued.
The current stock price of $31.49 is trading 25.4% above its estimated GF Value™ of $25.12.
GuruFocus considers Catalyst Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for CPRX:
3-Year Book Growth Rate: 39.70% (55% above median its 10-year median of 25.60)
GF Value™: $25.12 vs. price of $31.49 (25.4% above fair value)
No single metric tells the full story. See the CPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
70GF Score
Get the complete analysis for CPRX
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPRX has been successfully added to your 
